No Data
No Data
Zhitong A Share Sale Restriction Release List|May 17
According to the Zhitong Finance App, the ban on restricted shares of 13 listed companies was lifted on May 17, with a total market value of about 20.077 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of unbanned shares Shenzhen Sanda A000032, original shareholders placed 493 million, Lutai A000726 share incentives, 6.795 million, Guohai Securities 000750 issued additional A shares, original shareholders placed 352 million, Nasda002180 equity incentives, restricted circulation 1,154 million Jiujiang Biotech 300406 share incentives to limit sales and circulation 4076 million
Jiuqiang Biotech (300406.SZ) announced first-quarter results, net profit of 121 million yuan, an increase of 8.67%
Jiuqiang Biotech (300406.SZ) released its report for the first quarter of 2024, achieving operating income of 3.9 during the reporting period...
Jiuqiang Biotech (300406.SZ) obtained a medical device registration certificate
Jiuqiang Biotech (300406.SZ) announced that the company received the “Medical Device Registration...” issued by the State Drug Administration
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Jiuqiang Biotech (300406.SZ): Net profit in 2023 increased 34.6% year-on-year, and plans to distribute 2 yuan for 10 shares
Gelonghui March 29 丨 Jiuqiang Biotech (300406.SZ) released its 2023 annual report. The company achieved operating income of 174,16.267 million yuan, an increase of 15.27% over the previous year; total profit of 593.5546 million yuan, an increase of 32.09% over the previous year; the total equity of owners attributable to shareholders of listed companies was 372,459.19 yuan, an increase of 13.86% over the previous year; and net profit attributable to shareholders of listed companies was 52,374.28 yuan, an increase of 34.60% over the previous year. A cash dividend of 2 yuan is distributed to all shareholders for every 10 shares.
Jiuqiang Biotech (300406.SZ) subsidiary completed 24 Class I medical device registrations
Jiuqiang Biotech (300406.SZ) announced that Fuzhou Maixin Biotechnology Development Co., Ltd., a wholly-owned subsidiary of the company, recently...
No Data